Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=1820&ordering=-end_planned
{ "count": 2329, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=1840&ordering=-end_planned", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=1800&ordering=-end_planned", "results": [ { "id": 1992, "title": { "de": "Laserakupunktur als unterstützende Therapie beim Neugeborenen mit Entzugssyndrom aufgrund mütterlicher Substitutionstherapie", "en": "Laserakupunktur als unterstützende Therapie beim Neugeborenen mit Entzugssyndrom aufgrund mütterlicher Substitutionstherapie" }, "short": "LASERAKUP_NEUGEB_ENTZUG", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-07-01T02:00:00+02:00", "begin_effective": "2009-07-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2009-11-26T15:43:39+01:00", "program": null, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2872, "title": { "de": "Chordom - Charakterisierung der MUG-Chor1 Zelllinie", "en": "Chordoma - Characterizing MUG-Chor1 cell line" }, "short": "Chordoma", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2012-04-01T02:00:00+02:00", "begin_effective": "2012-04-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2012-05-24T12:00:53+02:00", "program": null, "subprogram": null, "organization": 14017, "category": 10, "type": 10, "partner_function": 4, "manager": 54171, "contact": 54171, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 530 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2872-54171-10" ] }, { "id": 2521, "title": { "de": "NEUE WIRKSTOFFE ZUR THERAPIE GASTROENTEROPANKREATISCHER TUMOREN (CARCINOIDS)", "en": "NOVEL AGENTS FOR THERAPY OF GASTROENTEROPANCREATIC TUMORS (CARCINOIDS)" }, "short": "CARCINOID THERAPY", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2011-07-06T10:24:22+02:00", "program": null, "subprogram": "Stadt Graz Kulturamt - Wissenschaft", "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2386, "title": { "de": "Europäisches Forschungs-Ethikkommissions-Netzwerk", "en": "European Research Ethics Committees Network" }, "short": "EURECNET", "url": "http://www.eurecnet.org/index.html", "abstract": { "de": null, "en": "EURECNET is a network that brings together national REC associations, networks or comparable initiatives but also other bodies relevant in the field of research involving human participants like National Ethics Councils and the European Commission's ethical review system. Such a network forms the infrastructural basis to promote awareness of specific working practices of RECs across Europe, to enhance the shared knowledge base of European RECs, to support coherent reviews and opinions and to meet new challenges and emerging ethical issues. The central objective of EURECNET as a Coordinating Action is to foster the already existing network of European REC networks (in short 'EUREC').\r\n\r\nIn particular, the contribution of EURECNET aims at five different levels:\r\n- fostering a sustainable infrastructure for European RECs (including a statute and a secretariat) to promote exchange and cooperation and to allow for international cooperation;\r\n- gathering information on RECs in Europe to build a basis for mutual exchange - collecting and evaluating training materials for REC members to enhance the quality of review;\r\n- conducting capacity building to facilitate the development of national REC networks (as future partners of EUREC);\r\n- identifying emerging ethical issues to develop common solutions for challenges posed by new technologies and scientific methodologies." }, "begin_planned": "2009-07-01T02:00:00+02:00", "begin_effective": "2011-03-01T01:00:00+01:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2014-08-31T02:00:00+02:00", "assignment": "2011-01-31T12:01:32+01:00", "program": 24, "subprogram": "Area: 5.1.1.2 Research on Ethics in science and technology\r\nTopic: SiS-2009-1.1.2.2 Networking and capacity-building activities to support ethics committees:", "organization": 14038, "category": 10, "type": 10, "partner_function": 2, "manager": 51627, "contact": 51627, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "244519", "ethics_committee": null, "edudract_number": null, "persons": [ "2386-51627-10" ] }, { "id": 2257, "title": { "de": "Einfluss unterschiedlicher Lichtspektren am Arbeitsplatz auf Physiologie und circadiane Rhythmik", "en": "Physiological and circadian effects of light in the work-place" }, "short": "Wirkung von Licht am Arbeitsplatz", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-07-01T02:00:00+02:00", "begin_effective": "2010-08-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2010-07-29T12:08:13+02:00", "program": 79, "subprogram": "Interdisziplinäre Humanmedizin", "organization": 14010, "category": 10, "type": 10, "partner_function": 4, "manager": 51671, "contact": 51671, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": "13891", "ethics_committee": null, "edudract_number": null, "persons": [ "2257-51671-10" ] }, { "id": 2921, "title": { "de": "NANOFAT Neue Hoffnung im Kampf gegen Adipositas: MicroRNA Drug Delivery für die Steigerung der Fettverbrennung im Fettgewebe", "en": "NANOFAT MicroRNA Drug Delivery as basis for increased fat burn in the adipose tissue" }, "short": "NANOFAT", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-05-01T02:00:00+02:00", "begin_effective": "2011-08-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2012-07-23T12:53:58+02:00", "program": null, "subprogram": "Human Technology Interface (HTI)", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2921-52854-10" ] }, { "id": 4261, "title": { "de": "TRPC\u2029 modulation \u2029by \u2029PKG\u2029 and \u2029Muscular \u2029Dystrophy", "en": "TRPC\u2029 modulation \u2029by \u2029PKG\u2029 and \u2029Muscular \u2029Dystrophy" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-01-01T01:00:00+01:00", "begin_effective": "2011-04-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2016-02-01T10:37:22+01:00", "program": 101, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 4, "manager": 58906, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 15 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "4261-58906-10" ] }, { "id": 1878, "title": { "de": "Anandamide/LPI signaling & function in endothelial cells", "en": "Anandamide/LPI signaling & function in endothelial cells" }, "short": "Anandamide/LPI", "url": null, "abstract": { "de": "Anandamide (ANA), also known as N-arachidonoylethanolamine, is a prominent substance of endocannabinoids, and exhibits multiple physiological functions in the brain, the immune system and the cardiovasculature. Although ANA is well known to contribute to human behavior, like eating and sleeping, and pain relief, evidence accumulated that ANA is an important vascular mediator that is released during tissue stress. LPI (lysophosphatidylinositol is another putatively important lipid mediator in the vessel wall.\r\nThe overall aim of this project is to explore ANA/LPI as important vascular mediators, to characterize their respective signal transduction, their interrelation and consequences to endothelial cell functions. In the end, our proposal aims to provide the scientific basis of consideration of the ANA/LPI system as therapeutic target for vascular-related medicine.", "en": "Anandamide (ANA), also known as N-arachidonoylethanolamine, is a prominent substance of endocannabinoids, and exhibits multiple physiological functions in the brain, the immune system and the cardiovasculature. Although ANA is well known to contribute to human behavior, like eating and sleeping, and pain relief, evidence accumulated that ANA is an important vascular mediator that is released during tissue stress. LPI (lysophosphatidylinositol is another putatively important lipid mediator in the vessel wall.\r\nThe overall aim of this project is to explore ANA/LPI as important vascular mediators, to characterize their respective signal transduction, their interrelation and consequences to endothelial cell functions. In the end, our proposal aims to provide the scientific basis of consideration of the ANA/LPI system as therapeutic target for vascular-related medicine." }, "begin_planned": "2009-07-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2013-09-30T02:00:00+02:00", "assignment": "2009-07-30T13:21:16+02:00", "program": 72, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 51860, "contact": 51860, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P21857", "ethics_committee": null, "edudract_number": null, "persons": [ "1878-50810-11", "1878-51860-10" ] }, { "id": 2635, "title": { "de": "Innovative Sensorik zur Quantifizierung kardialer Regelungsmechanismen bei Herzinsuffizienz (HI-Sens)", "en": "Innovative sensorics to quantify cardiac regulation in heart failure (HI-Sens)" }, "short": "HI-Sens", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-11-01T01:00:00+01:00", "end_planned": "2012-06-30T02:00:00+02:00", "end_effective": "2013-03-31T01:00:00+01:00", "assignment": "2011-11-15T11:13:18+01:00", "program": null, "subprogram": "Human Technology Interface", "organization": 14083, "category": 10, "type": 10, "partner_function": 2, "manager": 51700, "contact": 51700, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2635-51700-10" ] }, { "id": 2522, "title": { "de": "Semiautomatische Vermessung von CT-Datensätzen nach Augmentation des Sinus maxillaris zur Ermittlung der Veränderung des Augmentatvolumens in Abhängigkeit von der Zeit.", "en": "Semiautomatische Vermessung von CT-Datensätzen nach Augmentation des Sinus maxillaris zur Ermittlung der Veränderung des Augmentatvolumens in Abhängigkeit von der Zeit." }, "short": "Volumetrie in vivo", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-05-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2012-06-01T02:00:00+02:00", "end_effective": "2015-06-30T02:00:00+02:00", "assignment": "2011-07-06T15:12:29+02:00", "program": null, "subprogram": null, "organization": 14111, "category": 10, "type": 10, "partner_function": 4, "manager": 58106, "contact": 58106, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2522-58106-10" ] }, { "id": 2480, "title": { "de": "FET FlagShip: Information Technology Future of Medicine", "en": "FET FlagShip: Information Technology Future of Medicine" }, "short": "IT FoM", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-05-01T02:00:00+02:00", "begin_effective": "2011-05-01T02:00:00+02:00", "end_planned": "2012-06-01T02:00:00+02:00", "end_effective": "2012-04-30T02:00:00+02:00", "assignment": "2011-05-19T10:22:48+02:00", "program": 24, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": 51663, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": " 285609", "ethics_committee": null, "edudract_number": null, "persons": [ "2480-51663-10" ] }, { "id": 2985, "title": { "de": "Grazer Studie über die hormonellen Ursachen des arteriellen Bluthochdruckes (GECOH Studie)", "en": "Graz Endocrine Causes of Hypertension (GECOH) Study" }, "short": "GECOH Study", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2012-03-01T01:00:00+01:00", "begin_effective": "2012-03-01T01:00:00+01:00", "end_planned": "2012-06-01T02:00:00+02:00", "end_effective": "2012-06-01T02:00:00+02:00", "assignment": "2012-09-24T12:56:43+02:00", "program": null, "subprogram": "Land Steiermark: Förderung wissenschaftlicher (Forschungs)Projekte", "organization": 14080, "category": 10, "type": 10, "partner_function": 4, "manager": 53344, "contact": 53344, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2985-53344-10" ] }, { "id": 2394, "title": { "de": "CXCL13 Chemokin als neuer Biomarker bei systemischer Sklerodermie", "en": "CXCL13 Chemokine - a putative biomarker in systemic sclerosis" }, "short": "CXCL13 bei Sklerodermie", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-01-01T01:00:00+01:00", "begin_effective": "2011-04-01T02:00:00+02:00", "end_planned": "2012-06-01T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2011-02-04T11:58:45+01:00", "program": 79, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2906, "title": { "de": "Der Einfluss der Proteinkinase D2 auf den Glukosemetabolismus von Glioblastomzellen.", "en": "Protein Kinase D2 and its influence on the glucose metabolism of glioblastoma cells." }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2012-03-01T01:00:00+01:00", "begin_effective": "2012-07-01T02:00:00+02:00", "end_planned": "2012-05-31T02:00:00+02:00", "end_effective": "2013-09-30T02:00:00+02:00", "assignment": "2012-06-28T10:34:12+02:00", "program": null, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 50990, "contact": 50990, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2906-50990-10" ] }, { "id": 1626, "title": { "de": "SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics", "en": "SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics" }, "short": "SPIDIA", "url": null, "abstract": { "de": "In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: *the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and *its scale is restraines to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool developers and assay developers, aims to develop quality guidelines for molecular in vitro diagnostics and to standardize the pre-analytical workflow in related procedures. Regarding the second point, SPIDIA aims to develop modern pre-analytical tools for diagnostic improving the stabilisation, handling and study of free biomolecules within blood, plasma, serum, tissues and tumours. Recent discoveries have revealed that RNA, DNA or proteins, released from pathological sites, like tumour cells or Alzheimer's disease brain lesions, into the blood or as a secondary blood based response to the disease can serve as biomarkers for early and reliable molecular diagnosis of such debilitating diseases. Further discoveries have shown that the cellular profiles of these molecules and structures in clinical samples can change during transport and storage thus making clinical assay results and pharmaceutical research unreliable or even impossible. It will therefore be a decisive prerequisite for future and current diagnostic assays to develop standards and new technologies, tools and devices that eliminate the human error in the pre-analytical steps of in vitro diagnostics. At this crucial moment in the development of molecular diagnostics, SPIDIA proposes an IP that reunites 7 private research companies (including 4 SMEs) and 8 public research organisms, including universities, hospitals and biobanks and an official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on human health.", "en": "In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: *the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and *its scale is restraines to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool developers and assay developers, aims to develop quality guidelines for molecular in vitro diagnostics and to standardize the pre-analytical workflow in related procedures. Regarding the second point, SPIDIA aims to develop modern pre-analytical tools for diagnostic improving the stabilisation, handling and study of free biomolecules within blood, plasma, serum, tissues and tumours. Recent discoveries have revealed that RNA, DNA or proteins, released from pathological sites, like tumour cells or Alzheimer's disease brain lesions, into the blood or as a secondary blood based response to the disease can serve as biomarkers for early and reliable molecular diagnosis of such debilitating diseases. Further discoveries have shown that the cellular profiles of these molecules and structures in clinical samples can change during transport and storage thus making clinical assay results and pharmaceutical research unreliable or even impossible. It will therefore be a decisive prerequisite for future and current diagnostic assays to develop standards and new technologies, tools and devices that eliminate the human error in the pre-analytical steps of in vitro diagnostics. At this crucial moment in the development of molecular diagnostics, SPIDIA proposes an IP that reunites 7 private research companies (including 4 SMEs) and 8 public research organisms, including universities, hospitals and biobanks and an official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on human health." }, "begin_planned": "2008-06-01T02:00:00+02:00", "begin_effective": "2008-10-01T02:00:00+02:00", "end_planned": "2012-05-31T02:00:00+02:00", "end_effective": "2013-03-31T01:00:00+01:00", "assignment": "2008-10-01T13:12:38+02:00", "program": 24, "subprogram": "HEALTH-2007-1.2-5", "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1626-54279-12", "1626-51663-10" ] }, { "id": 2812, "title": { "de": "Verletzungen durch Verkehrsunfälle bei Patienten mit Parkinsonerkrankung", "en": "Injuries through road accidents in patients with Parkinson's disease" }, "short": "Parkinson und Verkehrsunfälle", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-12-01T01:00:00+01:00", "end_planned": "2012-05-30T02:00:00+02:00", "end_effective": "2015-01-31T01:00:00+01:00", "assignment": "2012-02-28T10:50:32+01:00", "program": null, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 4, "manager": 51959, "contact": 51959, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2812-51959-10" ] }, { "id": 2941, "title": { "de": "Kognition bei bipolar affektiver Störung", "en": "cognitive function in bipolar disorder" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2012-03-01T01:00:00+01:00", "begin_effective": "2012-09-01T02:00:00+02:00", "end_planned": "2012-05-01T02:00:00+02:00", "end_effective": "2013-12-31T01:00:00+01:00", "assignment": "2012-08-13T15:51:24+02:00", "program": null, "subprogram": null, "organization": 29444, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1720, "title": { "de": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)", "en": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)" }, "short": "GATIB II_GENAU_III_Trauner", "url": null, "abstract": { "de": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.", "en": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2009-01-15T10:32:33+01:00", "program": 73, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2104, "title": { "de": "Refining the basophil activation test (BAT) for the diagnosis of Hymenoptera venom allergy", "en": "Refining the basophil activation test (BAT) for the diagnosis of Hymenoptera venom allergy" }, "short": "BAT_09", "url": null, "abstract": { "de": "Weiterentwicklung des Basophilen-Aktivierungstests (BAT) für die Diagnostik der Insektengiftallergie\r\n\r\nZur Routinediagnostik einer Insektengiftallergie gehören Anamnese, Hauttests und die Bestimmung spezifischer IgE Antikörper im Serum. Leider führen diese Verfahren manchmal zu inkonkulsiven Ergebnissen. In den letzten Jahren hat sich der Basophilenaktivierungstest (BAT) als nützliche zusätzliche Methode bewährt. Ein Nachteil des BAT ist jedoch, dass durch den Grad der Zellaktivierung im Test sich kein Rückschluss auf den Schweregrad der allergischen Reaktion ziehen lässt. Ferner sind Daten verschiedener Labors kaum vergleichbar, da es kein standardisiertes Protokoll gibt. Um nun die Möglichkeiten der Allergiediagnostik zu optimieren und für den betroffen Patienten die bestmögliche Versorgung sicherzustellen ist es unerlässlich, auf diesem Gebiet nach weiteren neuen Ansatzpunkten zu suchen. Ziel des Projektes ist es daher einen auf der Expression verschiedener neuer Oberflächenmarker basierenden Basophilenaktivierungstest für die Diagnostik der Insektengiftallergie zu entwickeln.\r\n", "en": null }, "begin_planned": "2010-05-01T02:00:00+02:00", "begin_effective": "2010-05-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-04-30T02:00:00+02:00", "assignment": "2010-02-10T17:29:56+01:00", "program": null, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 87717, "contact": 87717, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 1161 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2104-87717-10" ] }, { "id": 1908, "title": { "de": "GATiB II - Subprojekt 1", "en": "GATiB II - Subproject 1" }, "short": "GATiB II - Subprojekt 1", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2009-09-03T17:01:48+02:00", "program": 73, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1908-51663-10" ] } ] }